ATE241380T1 - Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren - Google Patents

Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Info

Publication number
ATE241380T1
ATE241380T1 AT00916545T AT00916545T ATE241380T1 AT E241380 T1 ATE241380 T1 AT E241380T1 AT 00916545 T AT00916545 T AT 00916545T AT 00916545 T AT00916545 T AT 00916545T AT E241380 T1 ATE241380 T1 AT E241380T1
Authority
AT
Austria
Prior art keywords
vascular permeability
modulation
tie2 receptor
receptor activators
mammal
Prior art date
Application number
AT00916545T
Other languages
English (en)
Inventor
Chitra Suri
George D Yancopoulos
Gavin Thurston
Donald Mcdonald
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE241380T1 publication Critical patent/ATE241380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00916545T 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren ATE241380T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (1)

Publication Number Publication Date
ATE241380T1 true ATE241380T1 (de) 2003-06-15

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916545T ATE241380T1 (de) 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Country Status (14)

Country Link
EP (1) EP1165115B1 (de)
JP (1) JP2002540165A (de)
AT (1) ATE241380T1 (de)
AU (1) AU769198B2 (de)
CA (1) CA2368670C (de)
DE (1) DE60003011T2 (de)
DK (1) DK1165115T3 (de)
ES (1) ES2199804T3 (de)
HK (1) HK1043537A1 (de)
IL (2) IL145504A0 (de)
NO (1) NO329198B1 (de)
NZ (1) NZ514434A (de)
PT (1) PT1165115E (de)
WO (1) WO2000057901A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
SG156668A1 (en) * 2004-10-19 2009-11-26 Amgen Inc Angiopoietin-2 specific binding agents
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CN101370519B (zh) * 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
TR201809280T4 (tr) 2009-01-12 2018-07-23 Aerpio Therapeutics Inc Vasküler sızıntı sendromunun tedavi edilmesine yönelik yöntemler.
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2835380B2 (de) 2013-07-29 2021-04-07 Samsung Electronics Co., Ltd Verfahren zur Blockierung von Gefäßdurchlässigkeit unter Verwendung eines Anti-ANG2-Antikörpers
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
EP3352856B1 (de) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Aktivatoren von tie-2 zur verwendung bei der behandlung des augeninnendrucks
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
ES2251740T3 (es) * 1996-08-23 2006-05-01 Ludwig Institute For Cancer Research Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
JP2002540165A (ja) 2002-11-26
NO20014673L (no) 2001-11-22
ES2199804T3 (es) 2004-03-01
PT1165115E (pt) 2003-10-31
NZ514434A (en) 2003-11-28
NO20014673D0 (no) 2001-09-26
DK1165115T3 (da) 2003-09-22
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08
HK1043537A1 (zh) 2002-09-20
DE60003011D1 (de) 2003-07-03
IL145504A0 (en) 2002-06-30
NO329198B1 (no) 2010-09-13
AU769198B2 (en) 2004-01-22
CA2368670A1 (en) 2000-10-05
AU3763400A (en) 2000-10-16
EP1165115A1 (de) 2002-01-02
IL145504A (en) 2008-08-07
WO2000057901A1 (en) 2000-10-05
EP1165115B1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE241380T1 (de) Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE60010098D1 (de) 28-epirapaloge
MXPA03002477A (es) N-acilsulfonamidas promotras de la apoptosis.
NO20021281L (no) Vaskul¶r beleggingssammensetning
TR200103094T2 (tr) ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
DE60137835D1 (de) Modifizierte zytokine für krebs therapie
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
AP2001002274A0 (en) Rescorcinol derivatives.
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
ID26703A (id) Penggunaan anestesi lokal untuk sakit kepala vaskular
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69631500D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner
DE69732784D1 (de) Inhibierung von invasiver remodulierung
DE50010740D1 (de) Färbemittel und verwendung
DE60233819D1 (de) Doppelester
UA34245A (uk) Пристрій відображення графічної інформації
ITMI991903A0 (it) Pistola sparalamelle e/o groppini particolarmente utilizata per cornic i e simili

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165115

Country of ref document: EP